Exactly right, totally agree. In saying that,I also consider...

Exactly right, totally agree.

In saying that,
I also consider where he spent the most time
How big his stake is, his education & experience etc.

RAC is by far in large weighted to the positive side over any other company he has visibly invested in. And continues to invest in when there’s another particularly interesting biotech, that I would argue is nearer term, lower risk, & a much smaller part of his portfolio.

I do wonder, what RAC might have in store for us that we don’t know about if he’s throwing $300k+ into it on top of 16m shares, when the other one might be the better suited choice right now. (To someone on the outside that can’t see in)